KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Deffered Revenue (2016 - 2020)

Rigel Pharmaceuticals has reported Non-Current Deffered Revenue over the past 11 years, most recently at $146000.0 for Q3 2020.

  • Quarterly results put Non-Current Deffered Revenue at $146000.0 for Q3 2020, down 99.42% from a year ago — trailing twelve months through Sep 2020 was $146000.0 (down 99.42% YoY), and the annual figure for FY2019 was $1.4 million, up 1460.0%.
  • Non-Current Deffered Revenue for Q3 2020 was $146000.0 at Rigel Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for RIGL hit a ceiling of $26.4 million in Q2 2019 and a floor of $90000.0 in Q4 2017.
  • Median Non-Current Deffered Revenue over the past 5 years was $1.2 million (2016), compared with a mean of $6.2 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 14720.79% in 2019 and later crashed 99.42% in 2020.
  • Rigel Pharmaceuticals' Non-Current Deffered Revenue stood at $279000.0 in 2016, then plummeted by 67.74% to $90000.0 in 2017, then changed by 0.0% to $90000.0 in 2018, then surged by 1460.0% to $1.4 million in 2019, then tumbled by 89.6% to $146000.0 in 2020.
  • The last three reported values for Non-Current Deffered Revenue were $146000.0 (Q3 2020), $1.6 million (Q1 2020), and $1.4 million (Q4 2019) per Business Quant data.